Study Comparing Apixaban Pill Versus Enoxaparin Shot to Prevent Blood Clots After Head and Neck Cancer Surgery

What this Trial Is About

Researchers are studying whether apixaban, a pill taken twice daily, is a safe and easier alternative to enoxaparin, a daily injection, for preventing blood clots after head and neck cancer surgery. The trial aims to find out if apixaban can be safely used instead of enoxaparin, how patients feel about taking each medicine, and how well patients follow their treatment plans. This is a Phase 4, open-label, randomized study comparing two treatments for clot prevention after surgery. Participants will be assigned to one of two groups one group takes apixaban orally twice a day for 10 days starting 12 to 24 hours after surgery, while the other group receives enoxaparin as a daily injection for 10 days after surgery. Both treatments are aimed at preventing deep vein thrombosis DVT. The study includes follow-up visits to monitor safety and treatment adherence. During the study, participants will keep a medication diary and return unused medicine to check adherence. They will complete short surveys about their satisfaction with the medication. An ultrasound of the legs will be performed 11 to 14 days after surgery to check for blood clots. Follow-up visits will occur around 40 and 80 days after surgery to assess safety. Overall participation lasts about four months from surgery through the last follow-up visit.

Apixaban or Enoxaparin After Head and Neck Cancer Surgery